Findings

What do systematic reviews say?

4,771 questions · 10,185 findings · 893 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,109 · 20.7%GRADE not reported 1,125 · 11%Very low 2,279 · 22.4%Low 2,514 · 24.7%Moderate 1,709 · 16.8%High 449 · 4.4%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: total score · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 382 participants
Moderate

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

FEV1 % predicted: relative change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
6 participants
GRADE not reported

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

FEV1 % predicted: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 382 participants
Moderate

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 634 participants
Moderate

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Time to first pulmonary exacerbation · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Survival · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 603 participants
High

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: total score · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 599 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

FEV1 % predicted: relative change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 603 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

FEV1 % predicted: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 578 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 603 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Time to first pulmonary exacerbation · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment

Death (all causes) · people with diabetes and kidney disease

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low

Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment

Cardiovascular mortality · people with diabetes and kidney disease

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low

Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment

Doubling of SCr · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment

Fatal or nonfatal stroke · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment

Micro‐ to macroalbuminuria5 · people with diabetes and kidney disease

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
0.1 [0.05, 0.24]
1 study · 82 participants
Low

Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment

Micro‐ to normoalbuminuria6 · people with diabetes and kidney disease

It is very uncertain whether dual therapy (angiotensin‐converting‐enzyme inhibitors plus… changes micro‐ to normoalbuminuria6 compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
RR 5.27 [0.34, 81.57]
1 study · 82 participants
Very low